Patritumab-话题@MedSci

#Patritumab#

4篇内容 | 241人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1786782, encodeId=00581e8678216, content=<a href='/topic/show?id=8f3b13801a6' target=_blank style='color:#2F92EE;'>#Patritumab#</a>, objectTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, objectType=article, longId=206511, objectId=cbe82065113c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe82065113c, replyNumber=0, likeNumber=33, createdTime=2021-07-29, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe82065113c, moduleTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe82065113c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786783, encodeId=29b91e867830a, content=<a href='/topic/show?id=8f3b13801a6' target=_blank style='color:#2F92EE;'>#Patritumab#</a>, objectTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, objectType=article, longId=212480, objectId=b2a22124805f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2a22124805f, replyNumber=0, likeNumber=23, createdTime=2021-08-13, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2a22124805f, moduleTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2a22124805f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786781, encodeId=793c1e8678130, content=<a href='/topic/show?id=8f3b13801a6' target=_blank style='color:#2F92EE;'>#Patritumab#</a>, objectTitle=CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌, objectType=article, longId=159008, objectId=21e215900857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e215900857, replyNumber=0, likeNumber=32, createdTime=2019-03-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e215900857, moduleTitle=CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e215900857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786780, encodeId=859c1e8678065, content=<a href='/topic/show?id=8f3b13801a6' target=_blank style='color:#2F92EE;'>#Patritumab#</a>, objectTitle=临床试验失败，第一三共终止HER3单抗patritumab肺癌适应症研发, objectType=article, longId=70027, objectId=d17ee002788, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d17ee002788, replyNumber=0, likeNumber=30, createdTime=2017-05-10, rootId=0, userName=jiangfeng5067, userId=e0a1165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d17ee002788, moduleTitle=临床试验失败，第一三共终止HER3单抗patritumab肺癌适应症研发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d17ee002788)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Patritumab

2020-05-29

jiangfeng5067 (审核中...)

前往app查看评论内容

#Patritumab#

WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者

2021-07-29

jiangfeng5067 (审核中...)

前往app查看评论内容

#Patritumab#

ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应

2021-08-13

仁者大医 (审核中...)

前往app查看评论内容

#Patritumab#

CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌

2019-03-26

jiangfeng5067 (审核中...)

前往app查看评论内容

#Patritumab#

临床试验失败，第一三共终止HER3单抗patritumab肺癌适应症研发

2017-05-10

科室
- - 订阅+
  - 更多科室
工具
服务